📣 VC round data is live. Check it out!

Sera Prognostics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sera Prognostics and similar public comparables like Senzime, Outset Medical, Applied BioCode, FluoGuide and more.

Sera Prognostics Overview

About Sera Prognostics

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.


Founded

2008

HQ

United States

Employees

64

Financials (LTM)

Revenue: $215K
EBITDA: ($36M)

EV

$33M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sera Prognostics Financials

Sera Prognostics reported last 12-month revenue of $215K and negative EBITDA of ($36M).

In the same LTM period, Sera Prognostics generated $1K in gross profit, ($36M) in EBITDA losses, and had net loss of ($32M).

Revenue (LTM)


Sera Prognostics P&L

In the most recent fiscal year, Sera Prognostics reported revenue of $81K and EBITDA of ($31M).

Sera Prognostics is unprofitable as of last fiscal year, with gross margin of (102%), EBITDA margin of (38246%), and net margin of (39417%).

See analyst estimates for Sera Prognostics
LTMLast FY202320242025202620272028
Revenue$215K$81K$306K$77K$81K
Gross Profit$1K($83K)$96K($5K)($83K)
Gross Margin0%(102%)31%(6%)(102%)
EBITDA($36M)($31M)($35M)($32M)($31M)
EBITDA Margin(16821%)(38246%)(11532%)(41606%)(38246%)
EBIT Margin(16883%)(45062%)(13013%)(47578%)(45067%)
Net Profit($32M)($32M)($36M)($33M)($32M)
Net Margin(15084%)(39417%)(11844%)(42725%)(39417%)

Financial data powered by Morningstar, Inc.

Sera Prognostics Stock Performance

Sera Prognostics has current market cap of $78M, and enterprise value of $33M.

Market Cap Evolution


Sera Prognostics' stock price is $1.99.

Sera Prognostics share price increased by 2.6% in the last 30 days, and by 27.6% in the last year.

Sera Prognostics has an EPS (earnings per share) of $-0.82.

See more trading valuation data for Sera Prognostics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$33M$78M0.0%2.6%-13.1%27.6%$-0.82

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sera Prognostics Valuation Multiples

Sera Prognostics trades at 153.8x EV/Revenue multiple, and (0.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for Sera Prognostics

EV / Revenue (LTM)


Sera Prognostics Financial Valuation Multiples

As of May 26, 2026, Sera Prognostics has market cap of $78M and EV of $33M.

Sera Prognostics has a P/E ratio of (2.4x).

LTMLast FY202320242025202620272028
EV/Revenue153.8xn/m107.9xn/mn/m
EV/EBITDA(0.9x)(1.1x)(0.9x)(1.0x)(1.1x)
EV/EBIT(0.9x)(0.9x)(0.8x)(0.9x)(0.9x)
EV/Gross Profitn/mn/mn/mn/mn/m
P/E(2.4x)(2.4x)(2.2x)(2.4x)(2.4x)
EV/FCF(1.3x)(1.2x)(2.2x)(1.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sera Prognostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sera Prognostics Margins & Growth Rates

Sera Prognostics grew revenue by 413% and EBITDA by 19% in the last fiscal year.

In the most recent fiscal year, Sera Prognostics reported gross margin of (102%), EBITDA margin of (38246%), and net margin of (39417%).

See estimated margins and future growth rates for Sera Prognostics

Sera Prognostics Margins

Last FY202420252026202720282029
Gross Margin(102%)(6%)(102%)44%
EBITDA Margin(38246%)(41606%)(38246%)(8884%)
EBIT Margin(45062%)(47578%)(45067%)(8640%)
Net Margin(39417%)(42725%)(39417%)(7965%)
FCF Margin(32530%)(19857%)(32530%)

Sera Prognostics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth413%(75%)5%413%
Gross Profit Growth(318%)(105%)1560%(318%)
EBITDA Growth19%(9%)(3%)19%
EBIT Growth(2%)(8%)(0%)(2%)
Net Profit Growth4%(9%)(3%)4%
FCF Growth(44%)72%

Data powered by FactSet, Inc. and Morningstar, Inc.

Sera Prognostics Operational KPIs

Sera Prognostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.

Sera Prognostics' Rule of 40 is (8472%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sera Prognostics' Rule of X is (7853%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Sera Prognostics
LTMLast FY202320242025202620272028
Rule of 40(16229%)(8472%)
Bessemer Rule of X(15342%)(7853%)
Revenue per Employee$0.0M
Opex per Employee$0.6M
S&M Expenses to Revenue3809%8084%2728%7495%8084%
G&A Expenses to Revenue7777%20620%5341%20947%20620%
R&D Expenses to Revenue5663%16296%4975%19130%16260%
Opex to Revenue44964%13045%47571%44964%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sera Prognostics Competitors

Sera Prognostics competitors include Senzime, Outset Medical, Applied BioCode, FluoGuide, Creo Medical Group, Medicalgorithmics, Meta Biomed, LENSAR, Optiscan Imaging and Susmed.

Most Sera Prognostics public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Senzime6.1x5.2x(6.4x)(8.3x)
Outset Medical0.2x0.2x(0.5x)(0.6x)
Applied BioCode4.2x(14.0x)
FluoGuide(10.9x)(9.8x)
Creo Medical Group12.9x7.0x(2.0x)(4.1x)
Medicalgorithmics12.9x8.1x(25.8x)326.5x
Meta Biomed1.1x5.6x
LENSAR1.1x1.2x314.0x(87.2x)

This data is available for Pro users. Sign up to see all Sera Prognostics competitors and their valuation data.

Start Free Trial

Sera Prognostics Funding History

Before going public, Sera Prognostics raised $215M in total equity funding, across 7 rounds.


Sera Prognostics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Apr-21Series EaMoon Fund; Blue Ox Healthcare Partners; Elevance Health; Parian Global Management; Vivo Capital$100MSera Prognostics, Inc., a women's health company focused on improving maternal and neonatal outcomes through its proprietary proteomics and bioinformatics platform, completed a $100 million Series E financing on April 28, 2021. The round was supported by prominent healthcare investors including Blue Ox Healthcare Partners, Elevance Health (Anthem), aMoon Fund, Parian Global Management, and Vivo Capital, with Blue Ox and Elevance as leads. Funds were intended to expand commercialization of the PreTRM Test, a biomarker test predicting preterm birth risk, including building a specialty Ob/Gyn sales force. The company was at an early commercialization stage, leveraging its biobank data to develop tools for patients, doctors, payers, and researchers. New board members from investors joined, including representatives from Anthem and Vivo Capital, to support scaling as 'The Pregnancy Company.' Sera went public on Nasdaq (SERA) in 2021 and completed a $57.5 million follow-on offering in February 2025 to extend runway through 2028 and support U.S. expansion and EU preparations. Subsequent years showed slow revenue growth: $77,000 in 2024 and $81,000 in 2025, alongside ongoing operating losses and investments in R&D and sales. The PreTRM Test received a CMS pricing code of $750 in November 2021. Sera continues focusing on clinical validation like the PRIME study and broader applications in proteomics for pregnancy and potentially other medical areas, amid challenges in scaling revenue in the bioinformatics market.
Nov-19Series DBlue Ox Healthcare Partners$36MSera Prognostics, Inc. is a health diagnostics company focused on improving outcomes for women and babies through individualized prenatal care, particularly with its PreTRM test that assesses a pregnant woman's risk of spontaneous preterm birth using blood-based biomarkers as early as 19 weeks gestation. The company raised $36 million in an oversubscribed Series D financing round on November 13, 2019, led by Blue Ox Healthcare Partners alongside two strategic healthcare companies and participation from existing investors including Domain Associates, InterWest Partners, Laboratory Corporation of America Holdings, Catalyst Health Ventures, and Chione Ltd. The funds are intended to support commercialization of personalized medicine innovations in pregnancy care, scale the business, measure real-world clinical improvements and economic savings in collaboration with major health plans and providers, and advance market adoption of the PreTRM test to manage the clinical and economic challenges of preterm birth. Blue Ox Healthcare Partners, a private equity firm investing in growth-stage healthcare companies targeting individuality and value-based care, highlighted Sera's platform as reflective of industry transformation, positioning it for tremendous growth by enabling better outcomes at lower costs. Sera's CEO, Greg Critchfield, MD, MS, emphasized the strategic value of the new investors' expertise in healthcare, operations, and diagnostics. The round builds on prior financings, including a Series C of $40 million in 2017, contributing to Sera's total funding exceeding $267 million across multiple rounds by 2021. Sera continued raising capital post-Series D, with a Series D-II in early 2020, Series E of $100 million in 2021, and an IPO raising $75 million in July 2021, reflecting ongoing efforts to build commercial traction in the preterm birth risk assessment market.
Jan-17Series CCatalyst Health Ventures; Labcorp$40MSera Prognostics is a women's health diagnostics company developing the PreTRM test, a blood-based biomarker that predicts the risk of spontaneous preterm birth to enable earlier interventions and improve neonatal outcomes. The company, founded in 2008 and headquartered in Salt Lake City, Utah, focuses on precision pregnancy care using proteomics and bioinformatics platforms. In January 2017, Sera announced a $40 million Series C financing led by LabCorp, with participation from existing investors including Catalyst Health Ventures, Domain Associates, InterWest Partners, and the Bill & Melinda Gates Foundation. This round coincided with a strategic collaboration making LabCorp the exclusive U.S. distributor of the PreTRM test, leveraging LabCorp's network of 1,750 patient service centers to expand nationwide commercialization. Proceeds from the Series C were intended to build clinical evidence for reimbursement, support insurance coverage decisions, and scale commercialization efforts following a limited 2016 launch in select geographies. The partnership aimed to address the health and economic challenges of preterm birth, which experts noted could be mitigated through biomarker testing as a dominant strategy. Sera had previously raised funds across earlier rounds totaling approximately $44.3 million in 2011 and 2017 from investors like the Bill & Melinda Gates Foundation, Osage University Partners, Chione, Domain Associates, InterWest Partners, and Catalyst Health Ventures. Subsequent rounds included a $36 million Series D in late 2019 and a $100 million Series E in 2021 co-led by Anthem and Blue Ox Healthcare Partners. The company later pursued an IPO, filing to raise $75 million, with total funding reaching over $220 million from investors including LabCorp and Anthem.
Jan-15Series BCatalyst Health Ventures; Chione; Domain Associates; InterWest Partners; Upstart Life Ventures$20MSera Prognostics, Inc., a women's healthcare company focused on proteomic technology to predict preterm birth risk, closed an initial $20 million in Series B financing on January 7, 2015, led by Chione, Ltd, with participation from Domain Associates, InterWest Partners, Catalyst Health Ventures, UpStart Life Sciences Capital, and Osage University Partners. The funding supported the company's novel technology platform aimed at assessing individual preterm birth risk to enable earlier physician intervention, prolonging pregnancy and improving newborn health. At the time, Sera had completed enrollment of 5,500 patients in its Proteomic Assessment of Preterm Risk (PAPR) clinical study across 11 U.S. sites, with results expected in Q2 2015; PAPR was the largest U.S. singleton pregnancy proteomic study for developing a preterm birth predictor and validating the PreTRM test. In February 2015, the Series B was increased to $25 million with the addition of the Bill & Melinda Gates Foundation as a new investor, expanding the round to address global preterm birth challenges, particularly in developing countries. The additional funding aimed to develop new tests for preterm birth risk prediction worldwide. Sera Prognostics continued raising capital in subsequent years, including a $40 million Series C in 2017 and $36 million Series D in 2019 led by Blue Ox Healthcare Partners with returning investors like Domain Associates, InterWest Partners, Catalyst Health Ventures, and Chione, to support PreTRM test commercialization and clinical validation. The company later went public and pursued further growth in personalized prenatal care.
Nov-14Series BCatalyst Health Ventures; Chione; Domain Associates; Upstart Life Ventures$5MSera Prognostics, a women's healthcare company, closed an initial $20 million in Series B financing on January 7, 2015, led by Chione, Ltd, with participation from Domain Associates, InterWest Partners, Catalyst Health Ventures, UpStart Life Sciences Capital, and Osage University Partners. The round was later increased to $25 million with the addition of the Bill & Melinda Gates Foundation on February 4, 2015. A separate $5 million private equity round occurred in 2014 with investors not publicly disclosed, followed by a $9.2 million private equity round in the same year. The financing supported development of Sera's proteomic technology platform for assessing preterm birth risk to improve newborn health. Sera had completed enrollment of 5,500 patients in its Proteomic Assessment of Preterm Risk (PAPR) clinical study across 11 U.S. sites, with results expected in Q2 2015.
Jun-14Series A$9MSera Prognostics is a women's health diagnostics company focused on predicting preterm birth risk through proteomic analysis. In December 2014, the company announced its Series B financing, which reached $25 million after the Bill & Melinda Gates Foundation joined as a new investor in February 2015. The company was using the funds to expand its proteomic technology and develop diagnostic tests for pregnant women in developing countries. Sera had completed enrollment of 5,500 patients across eleven U.S. clinical sites in its landmark Proteomic Assessment of Preterm Risk (PAPR) clinical study, with results expected in the second quarter of 2015. The Series B was led by Chione, Ltd, Domain Associates, InterWest Partners, and Catalyst Health Ventures, with participation from existing investors and the new strategic backing of the Gates Foundation.
Mar-14Seed$5MSera Prognostics is a women's health diagnostics company developing innovative tests to predict preterm birth risk and other pregnancy complications. The company's flagship product, the PreTRM test, uses proprietary proteomic biomarkers to identify a woman's individualized risk for preterm birth early in pregnancy, enabling interventions to improve maternal and neonatal outcomes. In November 2011, Sera raised $19.3 million in Series A financing led by InterWest Partners, Domain Associates, and Catalyst Health Ventures, with participation from founder UpStart Life Sciences Capital and Osage University Partners. The company used Series A proceeds to complete its landmark Proteomic Assessment of Preterm Risk (PAPR) clinical trial, described as the largest singleton pregnancy proteomic study enrolled in the U.S. to date. By early 2015, Sera had expanded its Series B financing to $25 million with the Bill & Melinda Gates Foundation joining the round, demonstrating strong validation from both venture and philanthropic investors focused on advancing maternal health globally.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sera Prognostics

When was Sera Prognostics founded?Sera Prognostics was founded in 2008.
Where is Sera Prognostics headquartered?Sera Prognostics is headquartered in United States.
How many employees does Sera Prognostics have?As of today, Sera Prognostics has over 64 employees.
Who is the CEO of Sera Prognostics?Sera Prognostics' CEO is Evguenia Lindgardt.
Is Sera Prognostics publicly listed?Yes, Sera Prognostics is a public company listed on Nasdaq.
What is the stock symbol of Sera Prognostics?Sera Prognostics trades under SERA ticker.
When did Sera Prognostics go public?Sera Prognostics went public in 2021.
Who are competitors of Sera Prognostics?Sera Prognostics main competitors include Senzime, Outset Medical, Applied BioCode, FluoGuide, Creo Medical Group, Medicalgorithmics, Meta Biomed, LENSAR, Optiscan Imaging, Susmed.
What is the current market cap of Sera Prognostics?Sera Prognostics' current market cap is $78M.
What is the current revenue of Sera Prognostics?Sera Prognostics' last 12 months revenue is $215K.
What is the current revenue growth of Sera Prognostics?Sera Prognostics revenue growth (NTM/LTM) is 591%.
What is the current EV/Revenue multiple of Sera Prognostics?Current revenue multiple of Sera Prognostics is 153.8x.
Is Sera Prognostics profitable?No, Sera Prognostics is not profitable.
What is the current EBITDA of Sera Prognostics?Sera Prognostics has negative EBITDA and is not profitable.
What is Sera Prognostics' EBITDA margin?Sera Prognostics' last 12 months EBITDA margin is (16821%).
What is the current EV/EBITDA multiple of Sera Prognostics?Current EBITDA multiple of Sera Prognostics is (0.9x).
How many companies Sera Prognostics has acquired to date?Sera Prognostics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Sera Prognostics has invested to date?Sera Prognostics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Sera Prognostics

Lists including Sera Prognostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial